The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
NCT ID: NCT02188004
Last Updated: 2019-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4691 participants
OBSERVATIONAL
2014-06-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary purpose:Analyze risk factors of HPV infection and related diseases.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05584332
Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise
NCT01988948
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
NCT05026138
Clinical Study of HPV Therapeutic DNA Vaccine (NWRD08) in Patients With Cervical HPV16 and/or HPV18 Positive
NCT05905354
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
NCT06756269
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* residents of the study site;
* at least one sex partner;
* Be able to understand and comply with the request of the protocol.
Exclusion Criteria
* has received HPV vaccines.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Liuzhou center of disease prevention and control
UNKNOWN
Jun Zhang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jun Zhang
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Zhang
Role: STUDY_CHAIR
Xiamen University
Ming-Qiang Li
Role: PRINCIPAL_INVESTIGATOR
Liuzhou center of disease prevention and control
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liuzhou Center of disease prevention and control
Liuzhou, Guangxi, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wei F, Guo M, Huang S, Li M, Cui X, Su Y, Wu X, Ma X, Zheng Y, Huang Y, Wang L, Pan L, Wu T, Zhang J, Xia N. Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study. Clin Infect Dis. 2020 Jan 1;70(1):82-89. doi: 10.1093/cid/ciz168.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HPV-EPI-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.